Three generic drug manufacturers cannot claim damages for an injunction barring the release of cheaper versions of Effexor-XR, even if the injunction was later overturned, pharmaceutical giant Wyeth told a judge on day two of a six-week trial over its blockbuster antidepressant.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au